Results 51 to 60 of about 33,833 (238)

Drug-resistance mechanisms and tuberculosis drugs. [PDF]

, 2015
This publication presents independent research supported by the Health Innovation Challenge Fund (HICF-T5-342 and WT098600), a parallel funding partnership between the UK Department of Health and Wellcome Trust.This is the final version of the article ...
Abubakar, Ibrahim, Brown, Nicholas M, Burman, William J, Ellington, Matthew J, Feuerriegel, Silke, Ismail, Nazir A, Javid, Babak, Köser, Claudio U, Liddell, Kathleen, Moore, David, Niemann, Stefan, Peacock, Sharon J, Török, M Estée   +12 more
core   +3 more sources

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.

Lancet. Infectious Diseases (Print)
BACKGROUND The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal effect on non-replicating ...
M. Cevik, Lindsay C Thompson, C. Upton, V. Rolla, M. Malahleha, B. Mmbaga, N. Ngubane, Zamzurina Abu Bakar, M. Rassool, E. Variava, Rod Dawson, S. Staples, Umesh G. Lalloo, C. Louw, F. Conradie, Marika Eristavi, Anastasia G Samoilova, S. Skornyakov, N. Ntinginya, F. Haraka, G. PrayGod, Harriet Mayanja-Kizza, J. Caoili, V. Balanag, M. P. Dalcolmo, Timothy D Mchugh, R. Hunt, Priya Solanki, A. Bateson, A. Crook, Stella Fabiane, J. Timm, E. Sun, M. Spigelman, Derek J Sloan, S. H. Gillespie   +35 more
semanticscholar   +1 more source

Safety and Availability of Clofazimine in the Treatment of Multidrug and Extensively Drug-Resistant Tuberculosis: Analysis of Published Guidance and Meta-Analysis of Cohort Studies [PDF]

, 2013
Objectives: Given the spread of multidrug-resistant tuberculosis (MDR-TB), new therapies are urgently needed, including the repurposing of existing drugs. We aimed to assess key considerations for the clinical and programmatic use of clofazimine (Cfz), a
Dotsenko, Svetlana, Falzon, Dennis, Hwang, Thomas J, Jafarov, Azizkhon, Jaramillo, Ernesto, Keshavjee, Salmaan A., Lunte, Kaspars, Nunn, Paul, Wares, Douglas F., Weyer, Karin   +9 more
core   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

Exploring prospects of novel drugs for tuberculosis [PDF]

, 2012
Tuberculosis remains a disease with an enormous impact on public health worldwide. With the continuously increasing epidemic of drug-resistant tuberculosis, new drugs are desperately needed. However, even for the treatment of drug-sensitive tuberculosis,
Grobusch, M. P., Janssen, S., Jayachandran, R., Khathi, L., Pieters, J., Zinsstag, J.   +5 more
core   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA) [PDF]

, 2019
Bacterial resistance to antibiotics is widely regarded as a major public health concern with last resort MRSA treatments like vancomycin now encountering resistant strains.
Aínsa, José A, de la Fuente, Jesús M, De Matteis, Laura, Hibbitts, Alan, Lucía, Ainhoa, McArthur, Michael, Navarro, Fabrice, Serrano-Sevilla, Inés   +7 more
core   +2 more sources

Lung organoids as a human system for Mycobacteria infection modeling and drug testing

The FEBS Journal, EarlyView.
Mycobacterial infections, including tuberculosis (TB) and infections by nontuberculous mycobacteria (NTM), are still public health issues. In 2023, TB caused 1.25 million deaths, while NTM remain a clinical challenge for patients with cystic fibrosis (CF).
Stephen Adonai Leon‐Icaza, Romain Vergé, Raoul Mazars, Laurence Berry, Céline Cougoule   +4 more
wiley   +1 more source

Empirical ways to identify novel Bedaquiline resistance mutations in AtpE.

PLoS ONE, 2019
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical
Malancha Karmakar, Carlos H M Rodrigues, Kathryn E Holt, Sarah J Dunstan, Justin Denholm, David B Ascher   +5 more
doaj   +1 more source